{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.24","upperLimit":"24.22","value":"15.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Percentage of participants who achieved biochemical control defined as GH \\<1μg/L and IGF-1 \\<ULN at week 36.","dispersionType":"95% Confidence Interval","groups":[{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG000","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"Per-Protocol Set (PPS): consisted of a subset of the patients in the FAS who were compliant with requirements of the clinical study protocol. The protocol deviations criteria were defined prior to database lock. Per-protocol analysis was performed during the core phase, but not during the extension phase.","reportingStatus":"POSTED","timeFrame":"Wek 36","title":"Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}